Euronext Growth - Schedule One
Updated : 12:14
Pre-Admission Announcement
Euronext Growth Schedule 1
Announcement to be made by the Euronext Growth Applicant prior to admission in accordance with rule 2 of the Euronext Growth Rules for Companies | ||
All Applicants must complete the following | ||
Company name Venn Life Sciences Holdings plc |
| |
Company registered address and if different, company trading address (including postcodes) | ||
Registered Office:
PO Box W1J 6BD, Berkley Square House, 2nd Floor, Mayfair, London, W1J 8DJ
Trading Office:
19 Railway Road, Dalkey, Dublin, Ireland
| ||
Country of incorporation | England and Wales | |
Company website address containing all information required by rule 26 in the Euronext Growth Rules for Companies | ||
www.vennlifesciences.com/ and with effect from Admission, www.openorphan.com | ||
Company business (including main country of operation) or, in the case of an investing company, details of its investing strategy. If the admission is sought as a result of a reverse takeover under rule 14 of the Euronext Growth Rules for Companies, this should be stated
This is a reverse takeover under Rule 14.
Open Orphan is Clinical Research Organisation that specialises in rare and orphan drugs. The headquarters are in Dublin, Ireland and the company also has offices in France, the Netherlands and Germany. | ||
| ||
Details of securities to be admitted including any restrictions as to transfer of securities (i.e. where known, number of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares):
Number of ordinary shares of 0.01 pence each in nominal value ("Ordinary Shares") for which Admission will be sought: 253,493,259
Placing price per Ordinary Share: 5.6 pence
The are no restrictions as to the transferability of the Ordinary Shares and no Ordinary Shares will be held in treasury. | ||
| ||
Capital to be raised on admission (if applicable) and anticipated market capitalisation on admission:
Capital to be raised on admission: £4.5m (€5.0m)
Anticipated market capitalisation on admission: £14.1m (€15.8m)
|
| |||||||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||||
Percentage of Euronext Growth securities not in public hands on admission |
| |||||||||||||||||||||||||||||||||||
Approximately 31.1%
|
| |||||||||||||||||||||||||||||||||||
Details of any other exchange or trading platform to which the ex securities (or other securities of the company) are or will be admitted or traded: |
| |||||||||||||||||||||||||||||||||||
AIM
|
| |||||||||||||||||||||||||||||||||||
Full names and functions of directors and proposed directors (underlining the first name by which each is known or including any other name by which each is known): |
| |||||||||||||||||||||||||||||||||||
Directors:
Brendan Buckley, Non-executive Chairman Cathal Friel, Chief Executive Officer Christian Milla, Chief Operating Officer Tony Richardson, Corporate Development Officer Michael Ryan, Senior non-executive Director
Proposed Director:
Maurice Treacy, Executive Director
|
| |||||||||||||||||||||||||||||||||||
Full names and holdings of significant shareholders, expressed as a percentage of the issued share capital, before or after admission (underlining the first name by which each is known or including any other name by which each is known): | ||||||||||||||||||||||||||||||||||||
Before Admission
After Admission
| ||||||||||||||||||||||||||||||||||||
Names of all persons to be disclosed in accordance with schedule two, paragraph (h) of the Euronext Growth Rules for Companies: | ||||||||||||||||||||||||||||||||||||
n/a | ||||||||||||||||||||||||||||||||||||
i anticipated accounting reference date : 31 December |
| |||||||||||||||||||||||||||||||||||
ii date to which the main financial information in the admission document has been prepared: 31 December 2018 |
| |||||||||||||||||||||||||||||||||||
iii. dates by which it must publish its first three reports pursuant to Rules 18 and 19 in the Euronext Growth Rules for Companies: 30 June 2019 due September 2019, 31 December 2019 due 30 June 2020, 30 June 2020 due September 2020
|
| |||||||||||||||||||||||||||||||||||
Expected admission date: 28 June 2019
|
| |||||||||||||||||||||||||||||||||||
Name and address of Euronext Growth Advisor Davy Corporate Finance, Davy House, 49 Dawson Street, Dublin 2 |
| |||||||||||||||||||||||||||||||||||
Name and address of broker |
| |||||||||||||||||||||||||||||||||||
Arden Partners plc., 125 Old Broad Street, London, EC2N 1AR | ||||||||||||||||||||||||||||||||||||
Other than in the case of a quoted Applicant, details of where (postal or internet address) the admission document will be available from, with a statement that this will contain full details about the Applicant and the admission of its securities A copy of the admission document containing full details about the applicant and the admission of its securities will be available on the Company's website, www.vennlifesciences.com
| ||||||||||||||||||||||||||||||||||||
Date of notification 14 June 2019
|
| |||||||||||||||||||||||||||||||||||
New/update: New |
| |||||||||||||||||||||||||||||||||||
This announcement has been issued through the Companies Announcement Service of Euronext Dublin.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.